
CLAIMS

1. A compound of Formula (II-k):



, Formula (II-k), or a salt thereof, wherein:

Z^1 is cycloalkyl, heterocyclyl, aryl, or heteroaryl, optionally substituted with 1-5 R^5;

each of R^{2a} , R^{2b}, R^{2c}, and R^{2d} is independently hydrogen, alkyl, heteroalkyl, halo, cyano, nitro, or amino,;

or R^{2a} and R^{2b} or R^{2c} and R^{2d} are taken together to form an oxo group;

R^C and R^D are independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, or heteroaryl is optionally substituted with 1-6 R^6;

or R^C and R^D, taken together with the nitrogen atom to which they are attached, form a ring (e.g., a 5-7 membered ring), optionally substituted with 1-6 R^6;

each of R^3, R^5, and R^6 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, azido, oxo, $–OR^{A1}$, $–C(O)OR^{A1}$, $–C(O)R^{B1}$,$–OC(O)R^{B1}$, $–N(R^{C1})(R^{D1})$, $–N(R^{C1})C(O)R^{B1}$, $–C(O)N(R^{C1})$, SR^{E1}, cycloalkyl, heterocyclyl, aryl, heteroaryl;


each R^{A1}, R^{B1}, R^{C1}, R^{D1}, and R^{E1} is independently hydrogen, alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, wherein each of alkyl, alkenyl, alkynyl, heteroalkyl, cycloalkyl, heterocyclyl, aryl, heteroaryl is optionally substituted with 1-6 R^7;

each R^7 is independently alkyl, alkenyl, alkynyl, heteroalkyl, halogen, cyano, oxo, hydroxyl, cycloalkyl, or heterocyclyl;

m and n are each independently 0, 1, 2, 3, 4, 5, or 6;


p is 0, 1, 2, 3, or 4; and


q is an integer from 1 to 25,

wherein the triazolyl ring is  ;

provided that:

(i) when Z^1 is aryl, R^5 is not bicyclic heteroaryl; and (ii) the compound is not



or


.

2. The compound of claim 1, wherein each of R^{2a}, R^{2b}, R^{2c}, and R^{2d} is independently hydrogen or alkyl or one of R^{2a} and R^{2b} or R^{2c} and R^{2d} are taken together to form an oxo group.

3. The compound of claim 2, wherein each of R^{2a}, R^{2b}, R^{2c}, and R^{2d} is independently hydrogen.

4. The compound of any one of claims 1-3, wherein each of m and n is 1.

5. The compound of any one of claims 1-4, wherein q is an integer between 1 and 5.

6. The compound of any one of claims 1-5, wherein Z^1 is heterocyclyl.

7. The compound of claim 6, wherein Z^1 is a nitrogen-containing heterocyclyl, an oxygen-containing heterocyclyl, or a sulfur-containing heterocyclyl.

8. The compound of any one of claims 1-5, wherein Z^1 is aryl.

9. The compound of claim 8, wherein Z^1 is monosubstituted phenyl.

10. The compound of claim 8, wherein Z^1 is substituted with a nitrogen-containing group or an oxygen-containing group.

11. The compound of claim 10, wherein the 1 R^5 is in the ortho position or the para position.

12. The compound of any one of the preceding claims, wherein the compound of Formula (II-c) or Formula (II-k) is disposed on a surface, of a device.

13. The compound of any one of the preceding claims, wherein the compound is selected from a compound depicted in any one of Figures 1-6, or a pharmaceutically acceptable salt thereof.

14. A pharmaceutical composition comprising a compound of any one of the preceding claims and a pharmaceutically acceptable excipient.

15. A composition for use in treating a disease, disorder, or condition, or modulating an immune response in a subject, comprising a compound of any one of claims 1-13 or a composition of claim 14.

16. The composition for use of claim 15, wherein the composition comprises an implantable element.

17. The composition for use of any one of claims 15-16, wherein the composition is to be provided systemically or locally.

18. The composition for use of any one of claims 15-17, wherein the disorder or condition is a condition characterized by unwanted immune response.

19. The composition for use of any one of claims 15-18, wherein the disorder or condition is a condition characterized by an inadequate immune response.

20. The composition for use of any one of claims 15-19, wherein the composition is to be provided to downregulate an immune response.

21. The composition for use of any one of claim 15-20, wherein the composition reduces or is capable of reducing an unwanted reaction to the implantable element.

22. The composition for use of claim 16, wherein the implantable element (comprises a cell which provides a substance.

23. The composition for use of claim 22, wherein the cell is a retinal epithelial cell or an RPE-like cell.

24. The composition for use of claims 21-23, wherein the cell comprises an exogenous nucleic acid.

25. The composition for use of claim 24, wherein the exogenous nucleic acid encodes a polypeptide.

26. The composition for use of claim 25, wherein the polypeptide comprises an antibody.

27. The composition for use of claim 25, wherein the polypeptide is an enzyme.

28. The composition for use of claim 25, wherein the polypeptide comprises a clotting factor.

29. The composition for use of claim 25, wherein the polypeptide comprises Factor I, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, or Factor XIII.

30. The composition for use of claim 25, wherein the sequence of the polypeptide comprises at least one amino acid deletion, addition, or substitution relative to the sequence of Factor I, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, or Factor XIII.

31. The composition for use of claim 25, wherein the polypeptide is a replacement therapy or a replacement protein.

32. The composition for use of any one of claims 25-31, wherein the disease is a blood clotting disease or a lysosomal storage disease.

33. The composition for use of claims 16-32, wherein the implantable element is to be provided as a prophylactic treatment.

34. The composition for use of claims 16-33, wherein the implantable element is formulated for injection into a subject.

35. The composition for use of claims 16-33, wherein the implantable element is formulated for implantation into a subject.

36. The composition for use of claims 16-35, wherein the implantable element is to be implanted or to be injected into the lesser sac, into the omentum, or into the subcutaneous fat of a subject.

37. The composition for use of claims 16-36, wherein the implantable element is to be administered to a first subject having less than about 50%, 40%, 30%, 25%, 20%, 15%, 10%, 5%, 2%, or 1% of the polypeptide relative to a second subject, e.g., as determined by a blood test.

38. The composition for use of claims 16-37, wherein the level of a biomarker in a subject is monitored, e.g., in order to determine the level of efficacy of treatment.

39. An implantable element comprising a compound of any one of claims 1-13 or a composition of claim 14.

40. A device comprising a compound of any one of claims 1-13 or a composition of claim 14.

41. The device of claim 40, wherein the compound is disposed on a surface.

42. The device of any one of claims 40-41, wherein the compound is distributed evenly across the surface.

43. The device of any one of claims 40 - 41, wherein the compound is distributed unevenly across the surface.

44. The device of any one of claims 40-43, wherein the device is to be administered or to be provided to a subject for the treatment of a disease, disorder, or condition.

45. The device of any one of claims 40-44, wherein a first portion of the surface of the device comprises a compound of Formula (I) that modulates, an immune response and a second portion of the device lacks the compound, or has substantially lower density of the compound.

46. The device of any one of claims 40-44, wherein a first portion of the surface of the device comprises a compound of Formula I that modulates, e.g., down regulates, an immune response and a second portion of the surface comprises a second compound of Formula I.

47. The device of any one of claims 40-46, wherein the device comprises a cell.

48. The device of claim 47, wherein the cell is a retinal epithelial cell or an RPE-like cell.

49. The device of claims 40-48 wherein the cell comprises an exogenous nucleic acid.

50. The device of claim 49, wherein the exogenous nucleic acid encodes a polypeptide.

51. The device of claim 50, wherein the polypeptide comprises an antibody.

52. The device of claim 50, wherein the polypeptide is an enzyme.

53. The device of claim 50, wherein the polypeptide comprises a clotting factor.54. The device of claim 50, wherein the polypeptide comprises Factor I, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, or Factor XIII.

55. The device of claim 50, wherein the sequence of the polypeptide comprises at least one amino acid deletion, addition, or substitution relative to the sequence of Factor I, Factor II, Factor V, Factor VII, Factor VIII, Factor IX, Factor X, Factor XI, or Factor XIII.

56. The device of claim 50, wherein the polypeptide is a replacement therapy or a replacement protein.

57. The device of any one of claims 44-56, wherein the disease is a blood clotting disease or a lysosomal storage disease.

58. The device of claims 40-57, wherein the device is to be provided as a prophylactic treatment.

59. The device of claims 40-58, wherein the device is formulated for injection into a subject.

60. The device of claims 40-58 wherein the device is formulated for implantation into a subject.

61. The device of claims 40-60, wherein the device is to be implanted or to be injected into the lesser sac, into the omentum, or into the subcutaneous fat of a subject.